Developing a gene therapy pricing and access strategy plan
Our client, an established biopharma company, needed an early go-to-market pricing and access strategy for their haemophilia B gene therapy.
Putnam, an Ashfield Advisory company, was asked to determine the therapy’s value and translate that into an acceptable price point.
The team developed a robust value equation based on stakeholder feedback that was aligned to an estimated price with specific payment models. They also put together a detailed action plan to support market access.
Following Putnam’s recommendations, the client has begun implementing the plan and is preparing to launch the gene therapy at the proposed price point.
Discover more about EmerGENE
EmerGENE is the first multidisciplinary, global network of experts from across Ashfield and Sharp all passionately focused on the success of your cell and gene therapy.